Filter Results:
(481)
Show Results For
- All HBS Web (481)
- Faculty Publications (364)
Show Results For
- All HBS Web (481)
- Faculty Publications (364)
- February 2009
- Case
Avid Radiopharmaceuticals: The Venture Debt Question
By: Matthew Rhodes-Kropf and Ann Leamon
The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the... View Details
Keywords: Financial Crisis; Entrepreneurship; Borrowing and Debt; Venture Capital; Financial Management; Investment; Health Testing and Trials; Expansion; Biotechnology Industry; Biotechnology Industry
Rhodes-Kropf, Matthew, and Ann Leamon. "Avid Radiopharmaceuticals: The Venture Debt Question." Harvard Business School Case 809-086, February 2009.
- January 2009 (Revised July 2009)
- Case
Targanta Therapeutics: Hitting a Moving Target
By: Arthur A. Daemmrich
This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Decision Choices and Conditions; Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Business and Government Relations; Business Strategy; Biotechnology Industry; Biotechnology Industry
Daemmrich, Arthur A. "Targanta Therapeutics: Hitting a Moving Target." Harvard Business School Case 709-002, January 2009. (Revised July 2009.)
- September 2007 (Revised May 2009)
- Case
Syndexa and Technology Transfer at Harvard University
By: Richard G. Hamermesh and David Kiron
Gokhan Hotamisligil is a star researcher at Harvard School of Public Health who has made groundbreaking discoveries linking fat cells, inflammation, and diabetes. He now wants to form a company to commercialize these discoveries. At the same time, Isaac Kohlberg, the... View Details
Keywords: Business Startups; Higher Education; Entrepreneurship; Innovation and Invention; Intellectual Property; Rights; Agreements and Arrangements; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry
Hamermesh, Richard G., and David Kiron. "Syndexa and Technology Transfer at Harvard University." Harvard Business School Case 808-073, September 2007. (Revised May 2009.)
- November 2006 (Revised March 2008)
- Case
The Harvard Stem Cell Institute
Describes a set of issues confronting the leaders of the Harvard Stem Cell Institute, an innovative cross-university effort to accelerate scientific discovery and translation in the domain of stem cells. Covers a wide range of topics, including understanding how... View Details
Keywords: Talent and Talent Management; Higher Education; Entrepreneurship; Collaborative Innovation and Invention; Intellectual Property; Research and Development; Genetics; Biotechnology Industry; Biotechnology Industry; Massachusetts
Sahlman, William A. "The Harvard Stem Cell Institute." Harvard Business School Case 807-096, November 2006. (Revised March 2008.)
- November 2005 (Revised November 2005)
- Case
Massachusetts General Hospital and the Enbrel Royalty
By: David S. Scharfstein and Darren R. Smart
Massachusetts General Hospital is considering selling its royalty interest in Enbrel, Amgen's blockbuster drug for the treatment of rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer as well... View Details
Keywords: Valuation; Price; Investment Return; Capital; Value; Revenue; Health Care and Treatment; Health Industry; Health Industry; Massachusetts
Scharfstein, David S., and Darren R. Smart. "Massachusetts General Hospital and the Enbrel Royalty." Harvard Business School Case 206-075, November 2005. (Revised November 2005.)
- March 2005 (Revised August 2005)
- Case
Procurement at Betapharm Corp. (A)
Presents a move by Betapharm to centralize procurement and e-sourcing and the many control and incentive issues that arose subsequently. View Details
Keywords: Motivation and Incentives; Governance Controls; Supply Chain Management; Biotechnology Industry; Biotechnology Industry
Kulp, Susan L., and Taylor Randall. "Procurement at Betapharm Corp. (A)." Harvard Business School Case 105-030, March 2005. (Revised August 2005.)
- November 1998 (Revised October 1999)
- Case
E.I. du Pont de Nemours and Company (A)
Du Pont's chief executive must decide what steps to take as his company expands from commodity and specialized chemicals into biotechnology. View Details
West, Jonathan. "E.I. du Pont de Nemours and Company (A)." Harvard Business School Case 699-037, November 1998. (Revised October 1999.)
- September 1997 (Revised October 1997)
- Case
Bayer AG (A)
By: John A. Quelch
Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess... View Details
Keywords: Management Teams; Brands and Branding; War; Communication; Trademarks; Acquisition; Government and Politics; Biotechnology Industry; Biotechnology Industry; Germany; North America; United States
Quelch, John A., and Robin Root. "Bayer AG (A)." Harvard Business School Case 598-031, September 1997. (Revised October 1997.)
- 12 Oct 1999
- Research & Ideas
Porter’s Perspective: Competing in the Global Economy
you decide to put together this collection of articles? Porter: In retrospect, my work divides into three major areas. The first has to do with how firms compete in industries and gain competitive advantage. The next focuses on locations... View Details
Keywords: Re: Michael E. Porter
- 20 Mar 2012
- First Look
First Look: March 20
Market Governments—Qualitative Evidence from a Biotechnology Multinational Authors:Prithwiraj Choudhury, James Geraghty, and Tarun Khanna Publication:Global Strategy Journal 2, no. 1 (February 2012) Abstract We build on the emerging... View Details
Keywords: Sean Silverthorne
- 11 May 2010
- First Look
First Look: May 11
Amyris Biotechnologies: Commercializing Biofuel Gary P. Pisano and Alison Berkley WagonfeldHarvard Business School Case 610-031 In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert... View Details
Keywords: Martha Lagace
- 03 Aug 2010
- First Look
First Look: August 3
http://www.hbs.edu/research/pdf/11-005.pdf The Influence of Prior Industry Affiliation on Framing in Nascent Industries: The Evolution of Digital Cameras Authors:Mary J. Benner and Mary Tripsas Abstract New View Details
Keywords: Martha Lagace
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
Keywords: Venture Philanthropy; Biomedical Research; Investing For Impact; Innovation ＆ Entrepreneurship; Venture Capital; Science-Based Business; Philanthropy and Charitable Giving; Decision Making; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry
Myers, Kyle, and Scott Sawaya. "Myeloma Investment Fund." Harvard Business School Case 625-047, September 2024.
- November 2014
- Teaching Note
Claritas Genomics
By: Robert F. Higgins and Matthew G. Preble
Dr. Patrice Milos is the first CEO of Claritas Genomics (Claritas) and she faces a number of challenges in scaling the young company. Claritas was formed around a lab spun out from Boston Children's Hospital (BCH) which had performed genomic tests for the hospital. Now... View Details
- September 2014
- Case
Pfizer's Centers for Therapeutic Innovation (CTI)
By: Gary Pisano, James Weber and Kait Szydlowski
In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details
Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Biotechnology Industry; Biotechnology Industry; North and Central America; Europe; Asia
Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.
- December 2010
- Teaching Note
Roche's Acquisition of Genentech (TN)
By: Bo Becker and Carliss Y. Baldwin
Teaching Note for 210-040. View Details
- November 2009
- Case
The Explosion of Genetic Testing: Opportunities and Challenges
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
This case study invites the reader to consider genetic testing in several different lights. First, can the business of genetic testing be considered a disruptive innovation to the current drug therapy model as defined by Harvard Business School Professor Clay... View Details
- October 2009 (Revised July 2013)
- Case
Gilead Sciences, Inc.: Access Program
By: V. Kasturi Rangan and Katharine Lee
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details
Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Biotechnology Industry; Biotechnology Industry
Rangan, V. Kasturi, and Katharine Lee. "Gilead Sciences, Inc.: Access Program." Harvard Business School Case 510-029, October 2009. (Revised July 2013.)
- June 2008
- Case
Gordon Williams: Clinical Research at Brigham and Women's Hospital
By: H. Kent Bowen and Courtney Purrington
Clinical research is a critical element of biomedical research and development. This case describes the challenges of clinical research, and its role in bringing breakthroughs to patients. Dr. Williams leads through his own research and special programs to train... View Details
Keywords: Training; Health Care and Treatment; Success; Programs; Research and Development; Biotechnology Industry; Biotechnology Industry
Bowen, H. Kent, and Courtney Purrington. "Gordon Williams: Clinical Research at Brigham and Women's Hospital." Harvard Business School Case 608-168, June 2008.
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (D)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (D)." Harvard Business School Case 603-046, June 2003. (Revised October 2004.)